arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Roivant Sciences Ltd.

ROIV Health Care Biotechnology: Pharmaceutical Preparations
$37.45
▲ +7.2% Today
as of Oct 22, 16:51 ET
Last 30 days -8.70% Sep 14 → Oct 22
$32.74 $34.96 $37.18 $39.41 $41.63 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$36.68
High
$38.48
Low
$36.68
Volume
$13M
Avg Vol
$7M
Mkt Cap
$25.6B
P/E (TTM)
—
Beta
—
52w High
$42.50
52w Low
$17.89
Div Yield
—
Shares Out
$723M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 2 ● 16 ▼ 0
Oct 21 · 15:04 MarketBeat
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
Oct 21 · 13:09 Investing.com
Roivant Sciences stock surges on positive uveitis trial data
Oct 21 · 11:40 MT Newswires
Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis
▸ Show all 25 press releases & news Free account →

ROIV earnings at a glance

The options market is pricing a move of about ±9.6% after the report, a range of roughly $33.84 to $41.06 from today's $37.45. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±10.6% on average; after the most recent report on May 20, 2026 it moved +14.9%. That means options currently expect about the same movement than ROIV has typically delivered. ROIV beat the consensus EPS estimate in 2 of its last 5 reported quarters. Implied volatility is currently 82%. The share price of $37.45 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$18
$42
79% of range
Avg surprise (last 5)
-3.8%
Avg reaction (last 2)
+10.6%
100% positive
Latest IV / EM
82%
EM ±9.6% · $34 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.46$1.16$2.79$4.41$6.03 Actual $-0.20Est $-0.41Actual $-0.40Actual $6.03Actual $0.12Actual $-0.31Actual $0.23Actual $-0.31Est $-0.23Actual $-0.30Est $-0.31Actual $-0.40Est $-0.34Actual $-0.38Actual $-0.46Est $-0.38Actual $-0.26 Mar/2023SepDecJunSepDecMar/2025Jun/2025Sep/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-280M$-165M$-51M$63M$178M Sep 24Dec 24Jun 25Sep 25Dec 25Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.26 — — — — financials
Wed May 20, 2026Mar/2026 $-0.46 $-0.38 -21.1% -48.4% +14.9% earnings
Wed Dec 31, 2025Dec 2025 $-0.38 — — — — financials
Mon Nov 10, 2025Sep/2025 $-0.40 $-0.34 -17.6% — — earnings
Mon Aug 11, 2025Jun/2025 $-0.30 $-0.31 +3.2% — — earnings
Thu May 29, 2025Mar/2025 $-0.31 $-0.23 -34.8% — +6.4% earnings
Tue Dec 31, 2024Dec 2024 $0.23 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.31 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.12 — — — — financials
Sun Dec 31, 2023Dec 2023 $6.03 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.40 — — — — financials
Wed Jun 28, 2023Mar/2023 $-0.20 $-0.41 +51.2% — — earnings
Sat Dec 31, 2022Dec 2022 $-0.49 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1M—$2M$2M$2M—$9M$4M
Cost of revenue————————
Gross profit————————
Operating income$-366M—$-339M$-306M$-285M—$-274M$-342M
Net income$-190M—$-266M$-166M$-223M—$169M$-280M
EPS (diluted)$-0.26—$-0.38$-0.17$-0.33—$0.23$-0.31

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1.25B$1.42B$1.48B$1.24B$1.24B$2.72B$1.99B$1.96B
Inventory————————
Total current assets$4.74B$5.17B$4.66B$4.51B$4.62B$5.00B$5.36B$5.80B
Total assets$5.31B$5.71B$5.23B$5.06B$5.03B$5.44B$5.79B$6.21B
Long-term debt————————
Total liabilities$385M$416M$251M$257M$217M$250M$256M$626M
Total equity$4.23B$4.53B$4.27B$4.81B$4.82B$4.69B$5.54B$5.58B

Implied volatility — last 90 days

24%71%118%165%212% Jun 08 — IV 68% · EM ±9.0%Jun 09 — IV 46% · EM ±5.8%Jun 10 — IV 79% · EM ±9.3%Jun 11 — IV 46% · EM ±5.0%Jun 12 — IV 52% · EM ±5.3%Jun 15 — IV 96% · EM ±6.9%Jun 17 — IV 54% · EM ±2.2%Jun 19 — IV 43% · EM ±9.5%Jun 22 — IV 45% · EM ±9.4%Jun 23 — IV 61% · EM ±12.4%Jun 24 — IV 43% · EM ±8.6%Jun 25 — IV 46% · EM ±9.0%Jun 26 — IV 47% · EM ±9.0%Jun 29 — IV 24% · EM ±4.3%Jun 30 — IV 43% · EM ±7.3%Jul 01 — IV 33% · EM ±5.6%Jul 02 — IV 34% · EM ±5.5%Jul 03 — IV 35% · EM ±5.4%Jul 06 — IV 38% · EM ±5.2%Jul 10 — IV 66% · EM ±7.3%Jul 20 — IV 50% · EM ±11.8%Jul 21 — IV 63% · EM ±14.6%Jul 22 — IV 52% · EM ±11.8%Jul 23 — IV 62% · EM ±14.0%Jul 24 — IV 54% · EM ±11.9%Jul 27 — IV 66% · EM ±13.7%Jul 28 — IV 58% · EM ±11.9%Jul 29 — IV 65% · EM ±13.1%Jul 30 — IV 54% · EM ±10.5%Jul 31 — IV 62% · EM ±11.9%Aug 03 — IV 66% · EM ±11.7%Aug 04 — IV 55% · EM ±9.5%Aug 05 — IV 65% · EM ±10.8%Aug 06 — IV 54% · EM ±8.8%Aug 07 — IV 40% · EM ±6.3%Aug 10 — IV 43% · EM ±6.0%Aug 11 — IV 57% · EM ±7.5%Aug 12 — IV 40% · EM ±5.0%Aug 13 — IV 43% · EM ±5.1%Aug 14 — IV 49% · EM ±5.4%Aug 17 — IV 56% · EM ±4.7%Aug 18 — IV 74% · EM ±5.4%Aug 20 — IV 46% · EM ±1.9%Aug 24 — IV 51% · EM ±10.7%Aug 25 — IV 55% · EM ±11.3%Aug 26 — IV 49% · EM ±9.9%Aug 27 — IV 43% · EM ±8.4%Aug 28 — IV 53% · EM ±10.1%Aug 31 — IV 57% · EM ±10.1%Sep 01 — IV 52% · EM ±9.0%Sep 02 — IV 63% · EM ±10.5%Sep 03 — IV 64% · EM ±10.4%Sep 04 — IV 63% · EM ±9.8%Sep 07 — IV 71% · EM ±9.8%Sep 08 — IV 46% · EM ±6.1%Sep 09 — IV 48% · EM ±6.0%Sep 10 — IV 52% · EM ±6.2%Sep 11 — IV 36% · EM ±4.0%Sep 14 — IV 53% · EM ±4.4%Sep 15 — IV 65% · EM ±4.7%Sep 16 — IV 91% · EM ±5.4%Sep 17 — IV 212% · EM ±8.9%Sep 21 — IV 46% · EM ±9.6%Sep 22 — IV 51% · EM ±10.4%Sep 23 — IV 56% · EM ±11.1%Sep 24 — IV 54% · EM ±10.6%Sep 25 — IV 63% · EM ±12.1%Sep 28 — IV 51% · EM ±9.0%Sep 29 — IV 54% · EM ±9.3%Sep 30 — IV 41% · EM ±6.9%Oct 01 — IV 57% · EM ±9.3%Oct 02 — IV 51% · EM ±7.9%Oct 06 — IV 56% · EM ±7.4%Oct 07 — IV 77% · EM ±9.6%Oct 08 — IV 82% · EM ±9.6%

Sector peers

INSM
Insmed Incorporated
$22.2B $95.06-0.6%
VTRS
Viatris Inc.
$20.1B $18.48-0.9%
ASND
Ascendis Pharma A/S
$15.0B $242.99+3.7%
SMMT
Summit Therapeutics Inc.
$14.4B $15.55-3.4%
CORT
Corcept Therapeutics Incorporated
$12.9B $107.50-7.7%
ELAN
Elanco Animal Health Incorporated
$11.2B $22.69-0.0%

ROIV earnings FAQ

What is ROIV's expected move for earnings?

Options currently price a move of about ±9.6%, or $3.61 per share either way from $37.45.

How does ROIV stock usually react to earnings?

Across the last 2 reports the average next-day move was ±10.6%, up 2 times and down 0 times.

What is ROIV's implied volatility?

ROIV's at-the-money implied volatility is about 82% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in